Skip to main content

Table 2 Features of classical Hodgkin lymphoma (cHL)-type post-transplant lymphoproliferative disorder (PTLD) subsequent to another PTLD following liver transplantation

From: Classical Hodgkin lymphoma-type and monomorphic-type post-transplant lymphoproliferative disorder following liver transplantation: a case report

Case no.

Age/sex

Interval

Diagnosis

EBV positivity

Symptoms except lymphoadenopathy

Treatment

Outcome

Reference

1

64 years/M

5 years and 5 months from transplant

monomorphic PTLD

Fever, abdominal pain

Reduction of immunosupression, rituximab, 90Y-IT

*

Current case

  

1 year from the 1st PTLD

cHL PTLD

Fever

Surgery

CR

 

2

28 years/F

2 years and 2 months from transplant

Polymorphic PTLD

+

Fever

Reduction of immunosupression, acyclovir

CR

15

  

2 years and 5 months from the 1st PTLD

cHL PTLD

+

Fever, splenomegaly

Reduction of immunosupression, acyclovir, MOPP, splenectomy

CR

 

3

9 years/M

8 years from transplant

Polymorphic PTLD

+

Enlarged tonsil, adenoid

Reduction of immunosupression, acyclovir

CR

12

  

6 years and 10 months from the 1st PTLD

cHL PTLD

+

Mediastinal mass

COPP, ABV

CR

 

4

6 years/M

4 years and 2 months from transplant

Polymorphic PTLD

+

None

Reduction of immunosupression, gancyclovir

CR

14

  

1 year and 6 months from the 1st PTLD

cHL PTLD

+

Fever

MOPP, ABVD, radiation

CR

 
  1. PTLD post-transplant lymphoproliferative disorder, cHL classical Hodgkin lymphoma, M male, F female, 90Y-IT yttrium-90-ibritumomab tiuxetan, MOPP mechlorethamine, vincristine, procarbazine, prednisone, COPP cyclophosphamide, vincristin, procarbazine, prednisone, ABV doxorubicin, bleomycin, vinblastine, ABVD doxorubicin, bleomycin, vinblastine, dacarbazine, CR complete remission
  2. *The systemic lymphadenopathy resolved almost completely, except for the splenic hilar lesion composed of cHL-type PTLD